Mesoblast Limited (ASX:MSB): Ryoncil Revenue and Operating Cash Trends in Focus

Aditi Sarkar

19 October 2026 11:11 PM AEDT

Mesoblast Limited (ASX:MSB): Ryoncil Revenue and Operating Cash Trends in Focus

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

Mesoblast reported US$28 million in Ryoncil net revenue for the September 2026 quarter.
The company reported a 44% year-on-year increase from US$19 million.
Net operating cash spend decreased to US$2.3 million from US$14.9 million.
Cash stood at US$99 million on 30 September 2026.
The company reported 54 onboarded treatment sites for Ryoncil.

Mesoblast Limited (ASX:MSB) develops donor-derived cellular medicines for severe inflammatory conditions, using proprietary mesenchymal lineage cell technology. Its latest operational update, released on 16 October 2026, detailed Ryoncil revenue for the quarter ended 30 September 2026, changes in operating cash expenditure and the company’s available cash. These measures provide a current view of the commercial activity and spending associated with its cell therapy operations.

Ryoncil Sales Increase in the September Quarter

Mesoblast Limited (ASX:MSB) reported net revenue of US$28 million from Ryoncil for the September 2026 quarter, compared with US$19 million in the corresponding prior-year period. The company reported a 44% year-on-year increase. These figures were identified as preliminary management estimates, subject to customary closing and audit procedures.

Ryoncil, also known as remestemcel-L-rknd, is an approved cellular therapy for children aged two months and older with steroid-refractory acute graft-versus-host disease. This is a serious complication that can follow a stem-cell transplant. The September quarter revenue figure reflects sales of this approved treatment rather than income from the company’s other development programs.

Operating Cash Expenditure and Liquidity

For the same quarter, Mesoblast Limited (ASX:MSB) reported net operating cash spend of US$2.3 million, compared with US$14.9 million for the prior-year period. The company described this as an 85% improvement. Lower net cash spend alongside increased product revenue is a relevant measure of how current commercial receipts and operating requirements interact, although it is not equivalent to statutory profit.

Mesoblast reported US$99 million in cash at 30 September 2026. Its cash position remains relevant to product manufacturing, commercial operations and late-stage clinical development. The October update did not provide a complete audited quarterly financial statement, so the reported revenue and net operating cash expenditure should be read within the scope of that preliminary disclosure.

Treatment Sites and Commercial Activity

Mesoblast Limited (ASX:MSB) identified 54 onboarded sites in its latest release. Management also stated that September recorded the highest number of new patient starts in a month, following July and August scheduling patterns linked to the summer recess in the United States. The site count describes the company’s commercial network; it does not, by itself, establish the number of patients treated or future treatment volumes.

The FDA-approved indication for Ryoncil is specifically for paediatric steroid-refractory acute graft-versus-host disease. Distinguishing the approved indication from potential additional uses is important, because extensions to other patient groups or diseases require their own clinical and regulatory processes.

Additional Cell Therapy Programs

Beyond Ryoncil’s existing approved use, Mesoblast Limited (ASX:MSB) is developing its remestemcel-L platform for other inflammatory conditions, including adult graft-versus-host disease and biologic-resistant inflammatory bowel disease. It is also developing rexlemestrocel-L for chronic low back pain and heart failure. These programs are separate from the commercial revenue disclosed for the September quarter.

Clinical progression, regulatory submissions and manufacturing preparation involve different costs and timing considerations from sales of an approved medicine. The company said its capital allocation encompasses commercial manufacturing needs and late-stage clinical programs, while its revenue disclosure provides a measurable indication of present Ryoncil activity.

Key Insights

Mesoblast Limited (ASX:MSB) reported higher Ryoncil net revenue, lower net operating cash spend and US$99 million of cash for the September 2026 quarter. The figures indicate changes in the company’s disclosed commercial and cash activity, but the results remain preliminary. Future company filings can provide additional detail on revenue recognition, expenses and the progress of separate clinical programs.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.